|
CDX-301 Clinical Trials
3 actively recruiting trials across 3 locations
Also known as: Flt3 Ligand
Pipeline
Phase 1: 2Phase 2: 1
Top Sponsors
- Weill Medical College of Cornell University1
- University of Texas Southwestern Medical Center1
- Dana-Farber Cancer Institute1
Indications
- Cancer3
- Breast Cancer2
- Metastatic Breast Cancer1
- HER2-negative Breast Cancer1
- Metastatic Melanoma1
Los Angeles, California1 trial
Converting HR+ Breast Cancer Into an Individualized Vaccine
Cedars-Sinai Medical Center
Phase 2
Chicago, Illinois1 trial
CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer
University of Chicago Comprehensive Cancer Center
Phase 1
Boston, Massachusetts1 trial
NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma
Dana-Farber Cancer Institute
Phase 1
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.